These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28002804)

  • 1. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
    Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
    Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class I Phosphoinositide 3-Kinase
    Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CB/p110β is a selective survival factor for glioblastoma.
    Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
    Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells.
    Mazloumi Gavgani F; Karlsson T; Tangen IL; Morovicz AP; Arnesen VS; Turcu DC; Ninzima S; Spang K; Krakstad C; Guillermet-Guibert J; Lewis AE
    J Cell Sci; 2021 Feb; 134(3):. PubMed ID: 33536247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Significance and Mechanism of PI3K p110β Overexpression
 in Non-small Cell Lung Cancer].
    Xiong Y; Qu L; Li D; Wang Y; Li T
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):808-816. PubMed ID: 29277178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct epithelial-to-mesenchymal transitions induced by
    Gjelaj E; Hamel PA
    J Cell Sci; 2021 Feb; 134(4):. PubMed ID: 33526718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
    Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
    Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
    Zhang Z; Zhang L; Wang B; Wei R; Wang Y; Wan J; Zhang C; Zhao L; Zhu X; Zhang Y; Chu C; Guo Q; Yin X; Li X
    Cancer Lett; 2020 Jan; 469():54-67. PubMed ID: 31629932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
    Kim K; Lee HW
    Appl Immunohistochem Mol Morphol; 2018; 26(10):740-748. PubMed ID: 28549032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
    Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
    Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.
    Nakanishi Y; Walter K; Spoerke JM; O'Brien C; Huw LY; Hampton GM; Lackner MR
    Cancer Res; 2016 Mar; 76(5):1193-203. PubMed ID: 26759240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.
    Costa C; Ebi H; Martini M; Beausoleil SA; Faber AC; Jakubik CT; Huang A; Wang Y; Nishtala M; Hall B; Rikova K; Zhao J; Hirsch E; Benes CH; Engelman JA
    Cancer Cell; 2015 Jan; 27(1):97-108. PubMed ID: 25544637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
    Mjos S; Werner HMJ; Birkeland E; Holst F; Berg A; Halle MK; Tangen IL; Kusonmano K; Mauland KK; Oyan AM; Kalland KH; Lewis AE; Mills GB; Krakstad C; Trovik J; Salvesen HB; Hoivik EA
    Sci Rep; 2017 Aug; 7(1):10240. PubMed ID: 28860563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.